[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Camp4 Therapeutics Corp (CAMP)

Camp4 Therapeutics Corp (CAMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 233,667
  • Shares Outstanding, K 51,926
  • Annual Sales, $ 3,500 K
  • Annual Income, $ -80,400 K
  • EBIT $ -53 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.04
  • Price/Sales 66.80
  • Price/Cash Flow N/A
  • Price/Book 7.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 5
  • High Estimate $-0.21
  • Low Estimate $-0.25
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +62.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.80 +15.26%
on 05/05/26
5.01 -12.57%
on 05/13/26
-0.14 (-3.10%)
since 04/14/26
3-Month
3.50 +25.14%
on 02/17/26
7.75 -43.48%
on 03/09/26
+0.53 (+13.77%)
since 02/13/26
52-Week
1.30 +235.63%
on 06/20/25
7.75 -43.48%
on 03/09/26
+2.52 (+135.48%)
since 05/14/25

Most Recent Stories

More News
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence...

CAMP : 4.38 (-2.67%)
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1...

CAMP : 4.38 (-2.67%)
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered...

CAMP : 4.38 (-2.67%)
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)
CAMP4 Appoints Michael MacLean to its Board of Directors

CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)
CAMP4 to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance...

CAMP : 4.38 (-2.67%)
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 4.38 (-2.67%)

Business Summary

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based...

See More

Key Turning Points

3rd Resistance Point 5.14
2nd Resistance Point 4.95
1st Resistance Point 4.67
Last Price 4.38
1st Support Level 4.20
2nd Support Level 4.01
3rd Support Level 3.73

See More

52-Week High 7.75
Fibonacci 61.8% 5.29
Fibonacci 50% 4.53
Last Price 4.38
Fibonacci 38.2% 3.77
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.